Emerging data suggest Retatru tide , a dual agonist targeting both incretin and GIP , may provide a notable advancement for body loss . Preliminary patient tests have demonstrated impressive losses in visceral tissue, potentially outperforming current weight-loss treatments. Nevertheless , further assessment is needed to thoroughly assess its lasti